Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing

Journal of Psychopharmacology

Volumn 26, Issue 1, 2012, Pages 125-132

  Horder, Jamie ^a   Browning, Michael ^a   Di Simplicio, Martina ^a   Cowen, Philip J ^a   Harmer, Catherine J ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

Cannabinoids; CB1 antagonists; depression; endocannabinoids; facial expression recognition; healthy volunteers; memory; rimonabant

Indexed keywords

LACTOSE; PLACEBO; RIMONABANT;

ADULT; ANALYSIS OF VARIANCE; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; EMOTION; EMOTIONALITY; EYSENCK PERSONALITY QUESTIONNAIRE; FACIAL EMOTION RECOGNITION; FEMALE; HUMAN; MALE; MEMORY; PATTERN RECOGNITION; PERSONALITY; PRIORITY JOURNAL; PSYCHOLOGIC TEST; REY AUDITORY VERBAL LEARNING TASK; SIDE EFFECT; STATE TRAIT ANXIETY INVENTORY;

ADULT; ANXIETY DISORDERS; DEPRESSION; EMOTIONS; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECOGNITION (PSYCHOLOGY); YOUNG ADULT;

EID: 80053246977     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111400649     Document Type: Article

References (28)

1. Anderson NH. Likableness ratings of 555 personality-trait words. J Pers Soc Psychol. 1968 ; 9: 272-279
2. Beck AT. The evolution of the cognitive model of depression and its neurobiological correlates. Am J Psychiatry. 2008 ; 165: 969-977
3. Beyer CE, Dwyer JM, Piesla MJ, et al. Depression-like phenotype following chronic CB(1) receptor antagonism. Neurobiol Dis. 2010 ; 39: 148-155
4. Bouhuys AL, Geerts E, Gordijn MC. Depressed patients' perceptions of facial emotions in depressed and remitted states are associated with relapse: a longitudinal study. J Nerv Ment Dis. 1999 ; 187: 595-602 (Pubitemid 29489502)
5. Bradley BP, Mogg K, Williams R. Implicit and explicit memory for emotion-congruent information in clinical depression and anxiety. Behav Res Ther. 1995 ; 33: 755-770
6. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007 ; 370: 1706-1713 (Pubitemid 350100788)
7. Ekman P, Friesen WV Pictures of facial affect. Palo Alto, CA: Consulting Psychologists Press ; 1976 :
8. George DT, Herion DW, Jones CL, et al. Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology (Berl). 2009 ; 208: 37-44
9. Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry. 2005 ; 57: 261-267 (Pubitemid 40187370)
10. Gur RC, Erwin RJ, Gur RE, et al. Facial emotion discrimination: II. Behavioral findings in depression. Psychiatry Res. 1992 ; 42: 241-251
11. Haller J, Bakos N, Szirmay M, et al. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci. 2002 ; 16: 1395-1398 (Pubitemid 35340861)
12. Harmer CJ. Antidepressant drug action: a neuropsychological perspective. Depress Anxiety. 2010 ; 27: 231-233
13. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009 ; 195: 102-108
14. Horder J, Cowen PJ, Di Simplicio M, et al. Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology (Berl). 2009 ; 205: 85-91
15. Horder J, Harmer CJ, Cowen PJ, et al. Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. Int J Neuropsychopharmacol. 2010 ; 13: 1-11
16. Huestis MA, Boyd SJ, Heishman SJ, et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl). 2007 ; 194: 505-515 (Pubitemid 47492992)
17. Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid- oriented clinical research after CB(1) antagonists. Psychopharmacology (Berl). 2009 ; 205: 171-174
18. Lichtman AH. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur J Pharmacol. 2000 ; 404: 175-179
19. Mathews A, MacLeod C. Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol. 2005 ; 1: 167-195 (Pubitemid 43843950)
20. Moreira FA, Crippa JA. The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr. 2009 ; 31: 145-153
21. Navarro M, Hernandez E, Munoz RM, et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport. 1997 ; 8: 491-496 (Pubitemid 27180108)
22. Rey A L'examen de clinique en psychologie. Paris: Presses Universitaires de France ; 1964 :
23. Shiflett MW, Rankin AZ, Tomaszycki ML, et al. Cannabinoid inhibition improves memory in food-storing birds, but with a cost. Proc Biol Sci. 2004 ; 271: 2043-2048
24. Tallafuss A, Constable JR, Washbourne P. Organization of central synapses by adhesion molecules. Eur J Neurosci. 2010 ; 32: 198-206
25. Terranova JP, Storme JJ, Lafon N, et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl). 1996 ; 126: 165-172 (Pubitemid 26246767)
26. US Food and Drug Administration Advisory Committee (2007) FDA briefing document: Zimulti (rimonabant) Tablets, 20 mg. Available at:http://www.fda.gov/ OHRMS/DOCKETS/AC/07/briefing/2007-4306b1-00-index.htm (accessed 6 August 2007).
27. Witkin JM, Tzavara ET, Davis RJ, et al. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci. 2005 ; 26: 609-617 (Pubitemid 41636305)
28. Young AW, Rowland D, Calder AJ, et al. Facial expression megamix: tests of dimensional and category accounts of emotion recognition. Cognition. 1997 ; 63: 271-313 (Pubitemid 127432166)